[1] Cordonnier C, Demchuk A, Ziai W, Anderson CS. Intracerebral haemorrhage:current approaches to acute management[J]. Lancet, 2018, 392:1257-1268.
[2] Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MD, Barer DH; STICH Investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH):a randomised trial[J]. Lancet, 2005, 365:387-397.
[3] Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell PM; STICH Ⅱ Investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH Ⅱ):a randomised trial[J]. Lancet, 2013, 382:397-408.
[4] Ziai W, Nyquist P, Hanley DF. Surgical strategies for spontaneous intracerebral hemorrhage[J]. Semin Neurol, 2016, 36:261-268.
[5] Hanley DF, Thompson RE, Muschelli J, Rosenblum M, McBee N, Lane K, Bistran-Hall AJ, Mayo SW, Keyl P, Gandhi D, Morgan TC, Ullman N, Mould WA, Carhuapoma JR, Kase C, Ziai W, Thompson CB, Yenokyan G, Huang E, Broaddus WC, Graham RS, Aldrich EF, Dodd R, Wijman C, Caron JL, Huang J, Camarata P, Mendelow AD, Gregson B, Janis S, Vespa P, Martin N, Awad I, Zuccarello M; MISTIE Investigators. Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE):a randomised, controlled, open-label, phase 2 trial[J]. Lancet Neurol, 2016, 15:1228-1237.
[6] Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, Mayo SW, Bistran-Hall AJ, Gandhi D, Mould WA, Ullman N, Ali H, Carhuapoma JR, Kase CS, Lees KR, Dawson J, Wilson A, Betz JF, Sugar EA, Hao Y, Avadhani R, Caron JL, Harrigan MR, Carlson AP, Bulters D, LeDoux D, Huang J, Cobb C, Gupta G, Kitagawa R, Chicoine MR, Patel H, Dodd R, Camarata PJ, Wolfe S, Stadnik A, Money PL, Mitchell P, Sarabia R, Harnof S, Barzo P, Unterberg A, Teitelbaum JS, Wang W, Anderson CS, Mendelow AD, Gregson B, Janis S, Vespa P, Ziai W, Zuccarello M, Awad IA; MISTIE Ⅲ Investigators. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE Ⅲ):a randomised, controlled, open-label, blinded endpoint phase 3 trial[J]. Lancet, 2019, 393:1021-1032.
[7] Awad IA, Polster SP, Carrión-Penagos J, Thompson RE, Cao Y, Stadnik A, Money PL, Fam MD, Koskimäki J, Girard R, Lane K, McBee N, Ziai W, Hao Y, Dodd R, Carlson AP, Camarata PJ, Caron JL, Harrigan MR, Gregson BA, Mendelow AD, Zuccarello M, Hanley DF; MISTIE Ⅲ Trial Investigators. Surgical performance determines functional outcome benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) procedure[J]. Neurosurgery, 2019, 84:1157-1168.
[8] Vespa P, Hanley D, Betz J, Hoffer A, Engh J, Carter R, Nakaji P, Ogilvy C, Jallo J, Selman W, Bistran-Hall A, Lane K, McBee N, Saver J, Thompson RE, Martin N; ICES Investigators. ICES (Intraoperative Stereotactic Computed Tomography-Guided Endoscopic Surgery) for brain hemorrhage:a multicenter randomized controlled trial[J]. Stroke, 2016, 47:2749-2755.
[9] Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E, Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW, Zhang JL, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J; INTERACT Investigators. Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT):a randomised pilot trial[J]. Lancet Neurol, 2008, 7:391-399.
[10] Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, Lindley R, Robinson T, Lavados P, Neal B, Hata J, Arima H, Parsons M, Li Y, Wang J, Heritier S, Li Q, Woodward M, Simes RJ, Davis SM, Chalmers J; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage[J]. N Engl J Med, 2013, 368:2355-2365.
[11] Hemphill JC 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, Fung GL, Goldstein JN, Macdonald RL, Mitchell PH, Scott PA, Selim MH, Woo D; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2015, 46:2032-2060.
[12] Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage[J]. N Engl J Med, 2016, 375:1033-1043.
[13] Toyoda K, Koga M, Yamamoto H, Foster L, Palesch YY, Wang Y, Sakai N, Hara T, Hsu CY, Itabashi R, Sato S, Fukuda-Doi M, Steiner T, Yoon BW, Hanley DF, Qureshi AI; ATACH-2 Trial Investigators. Clinical outcomes depending on acute blood pressure after cerebral hemorrhage[J]. Ann Neurol, 2019, 85:105-113.
[14] Kapinos G, Hanley DF Jr. The systolic blood pressure sweet spot after intracerebral hemorrhage:130 mm Hg[J]? Neurology, 2018, 91:495-496.
[15] Sprigg N, Flaherty K, Appleton JP, Al-Shahi Salman R, Bereczki D, Beridze M, Christensen H, Ciccone A, Collins R, Czlonkowska A, Dineen RA, Duley L, Egea-Guerrero JJ, England TJ, Krishnan K, Laska AC, Law ZK, Ozturk S, Pocock SJ, Roberts I, Robinson TG, Roffe C, Seiffge D, Scutt P, Thanabalan J, Werring D, Whynes D, Bath PM; TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2):an international randomised, placebo-controlled, phase 3 superiority trial[J]. Lancet, 2018, 391:2107-2115.
[16] Selim M, Foster LD, Moy CS, Xi G, Hill MD, Morgenstern LB, Greenberg SM, James ML, Singh V, Clark WM, Norton C, Palesch YY, Yeatts SD; i-DEF Investigators. Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF):a multicentre, randomised, placebo-controlled, double-blind phase 2 trial[J]. Lancet Neurol, 2019, 18:428-438.
[17] Li Q, Zhang G, Huang YJ, Dong MX, Lv FJ, Wei X, Chen JJ, Zhang LJ, Qin XY, Xie P. Blend sign on computed tomography:novel and reliable predictor for early hematoma growth in patients with intracerebral hemorrhage[J]. Stroke, 2015, 46:2119-2123.
[18] Li Q, Zhang G, Xiong X, Wang XC, Yang WS, Li KW, Wei X, Xie P. Black hole sign:novel imaging marker that predicts hematoma growth in patients with intracerebral hemorrhage[J]. Stroke, 2016, 47:1777-1781.
[19] Li Q, Liu QJ, Yang WS, Wang XC, Zhao LB, Xiong X, Li R, Cao D, Zhu D, Wei X, Xie P. Island sign:an imaging predictor for early hematoma expansion and poor outcome in patients with intracerebral hemorrhage[J]. Stroke, 2017, 48:3019-3025.